A growth stage company focused on developing neuromodulation therapies to address chronic and debilitating conditions in children. We are dedicated to advancing science with our proprietary PENFS technology, which we developed. We believe that superior science and evidence-based research are necessary for adoption by the medical and scientific community. With one FDA indicationófunctional abdominal pain associated with IBS in adolescents 11-18 years oldóon the market, additional clinical trials of PENFS in multiple pediatric conditions are underway focused on unmet healthcare needs in children
